by Raynovich Rod | Nov 20, 2012 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
Markets Are Back To Fretting About Fiscal Cliff Bernanke scolded Congress on the fiscal cliff and markets turned down. Despite a lackluster market down about 0.3% there is a lot of green in biotech. Among the winners in the Rayno Life Science universe are: Albany...
by Raynovich Rod | Oct 23, 2012 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph, Clinical Diagnostics and Tools
Cepheid in Low $30’s- Long Term Buy Cepheid is not a cheap stock with a Price to Sales of 6.82, market cap of $2.10B and a forward PE of 122.58 but we see a capitulation of sellers who were playing the MO game with a very expensive stock. Nonetheless Cepheid is...
by Raynovich Rod | Jul 25, 2012 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph, Biopharmaceuticals
Rayno Life Science Focus Stocks Are Strong-TMO Added Biopharmaceutical stocks continue their run today beginning with higher sales expectations for Regeneron(REGN $128) with their eye drug for macular degeneration.Regeneron raised expectation for Eyelea to $700-750...
by Raynovich Rod | Jul 20, 2012 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
AACC Meeting Hangover Begins With Cepheid Earnings Cuts–Stock Off 24% on Volume of 7M shares Cepheid (CPHD) a leader in molecular diagnostics, forecasted earnings of 38-42 cents a share for the year down from 50-55 cents a share on expected revenues in the...
by Raynovich Rod | Jul 13, 2012 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
2012: Four Big Winners Up 30-40% in DX and Tools Portfolio: ABAX, EXAS, GPRO, ILMN In a volatile year with dire macro news and low growth forecasts the NASDAQ was up 10 % YTD and the Rayno Life Science Portfolio had its best year since 2010. M&A continues to play...
by Raynovich Rod | May 3, 2012 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph, Clinical Diagnostics and Tools
ALR ($21.58) Continues to Sell-off Slicing through 3 Mo. Technical Bottom We have included Alere in our diagnostics and tools portfolio since 2/2/09 at a price of $25, and although the stock is trading more than 10% under that price 3 years later, there was an...
by Rod Raynovich | Jun 9, 2011 | BIOgraph
The market rallied on the seventh day after six days of losses but we still have a few hours to go. The Dow is up 0.96% and the NAZ is up 0.64%.Life Science stocks are strong overall with mid-caps up 0.75%. Diagnostics and tools are the strongest sector and within...
by Rod Raynovich | Mar 24, 2011 | BIOgraph
On robust and active Life Science trading day two laggard diagnostic stocks perked up: Iris International (IRIS $9.41) is up 4.44% on FDA clearance of its iChem Velocity Workstation for automated Urine Chemistries. The stock is been trading from $9-10 over the past...
by Rod Raynovich | Jan 24, 2011 | BIOgraph
Novartis (NVS) acquires Genoptix(GXDX $24.84) for $470M-Stock is up 25% The biotech diagnostics and tools sector was ignited today with acquisition of Genoptix, a provider of laboratory services for hematology and oncology. Genoptix put itself up for sale in December...
by Rod Raynovich | Dec 6, 2010 | 2023-24 Life Science Portfolios, BIOgraph
Life Science ETF’s: Strategy and Composition There are several ETF’s with biotech and drug positions but the three that are large, liquid and better known with asset values are : First Trust Amex Arca Biotech Index (FBT,$166M) , iShares Nasdaq...
